Julie Milliken
Psychiatric/Mental Health · Cambridge, OHNPI 1104575034
Payments from drug & device makers
Across 169 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$424
- AbbVie$399
- Supernus Pharmaceuticals, Inc.$389
- Otsuka America Pharmaceutical, Inc.$317
- Alkermes, Inc.$234
- Johnson & Johnson$206
- plus $639 from 9 others
What the payments were for
- Food & beverage$2,609100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 35 | $424 |
| AbbVie | 37 | $399 |
| Supernus Pharmaceuticals, Inc. | 23 | $389 |
| Otsuka America Pharmaceutical, Inc. | 15 | $317 |
| Alkermes, Inc. | 13 | $234 |
| Johnson & Johnson | 10 | $206 |
| Lundbeck LLC | 12 | $198 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $156 |
| Indivior Inc. | 5 | $94 |
| Axsome Therapeutics, Inc. | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $46 |
| Neurocrine Biosciences, Inc. | 2 | $31 |
| Noven Therapeutics, LLC | 2 | $28 |
| Gilead | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
How this compares
$2,609 in reported general payments places this provider in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 37 | $55,893 |
| CaplytaLumateperone Tosylate | 18 | $29,575 |
| Divalproex Sodium | 35 | $2,039 |
| Aripiprazole | 25 | $1,831 |
| Escitalopram Oxalate | 41 | $1,099 |
| Oxcarbazepine | 35 | $714 |
| Prazosin Hcl | 30 | $481 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $478 |
| Trazodone Hcl | 68 | $469 |
| Olanzapine | 17 | $340 |
| Risperidone | 19 | $304 |
| Buspirone Hcl | 53 | $227 |
| Quetiapine Fumarate | 34 | $223 |
| Perphenazine | 16 | $217 |
| Lamotrigine | 26 | $206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $399 | $55,89337 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $156 | $29,57518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Cambridge
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
- Rachael McLaughlinMaple Heights$114K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.